https://crcwarriors.org/ 2026-08-26 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-08-26 daily 0.9 https://crcwarriors.org/medicamentos 2026-08-26 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-08-26 daily 0.8 https://crcwarriors.org/noticias 2026-08-26 daily 0.8 https://crcwarriors.org/combinaciones 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-08-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-08-01 monthly 0.7 https://crcwarriors.org/contacto 2026-08-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-08-01 monthly 0.6 https://crcwarriors.org/colabora 2026-08-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07775209/reduccion-de-la-duracion-del-tratamiento-con-radioterapia-mediante-el-uso-de-una-tecnica-de-refuerzo-integrado-simultaneo-con-una-dosis-de-radiacion-mas-baja-para-los-ganglios-linfaticos-electivos-y 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07775209/shortening-radiation-course-duration-using-simultaneous-integrated-boost-with-lower-intensity-elective-nodal-dosing-and-concurrent-chemotherapy-for-high-risk-anal-squamous-cell-carcinoma 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07781774/mejora-de-la-tasa-de-participacion-en-los-programas-de-deteccion-del-cancer-colorrectal-mediante-la-educacion-y-la-divulgacion-de-pruebas-basadas-en-el-analisis-de-heces 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07781774/improving-colorectal-cancer-screening-uptake-through-education-and-stool-based-testing-outreach 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07782164/eficacia-de-la-electroforesis-irreversible-ire-para-el-tratamiento-de-tumores-pelvicos-recurrentes-estudio-pelfire 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07782164/efficacy-of-irreversible-electroporation-ire-for-treating-recurrent-pelvic-tumors-pelfire-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07775859/nomad-gi-estrategia-de-manejo-no-quirurgico-y-preservacion-de-organos-guiada-por-biomarcadores-tras-terapia-de-precision-en-canceres-gastrointestinales 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07775859/nomad-gi-molecular-guided-non-operative-management-and-organ-preservation-strategy-after-precision-therapy-in-gastrointestinal-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07776548/desarrollo-y-validacion-de-un-marcador-de-adn-tumoral-circulante-para-tumores-colorrectales-preneoplasicos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07776548/development-and-validation-of-a-circulating-tumour-dna-marker-for-pre-neoplastic-colorectal-tumours 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07781852/evaluacion-de-la-distribucion-del-cm500-marcado-con-64cu-68ga-en-voluntarios-sanos-y-pacientes-con-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07781852/evaluation-of-the-distribution-of-64cu-68ga-labeled-cm500-in-healthy-volunteers-and-patients-with-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07781306/estudio-prospectivo-de-imagenes-de-metastasis-poem 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07781306/prospective-metastases-imaging-poem 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07108127/eficacia-y-seguridad-de-los-biosimilares-de-trastuzumab-y-los-biosimilares-de-pertuzumab-en-combinacion-con-quimioterapia-para-el-tratamiento-neoadyuvante-de-pacientes-con-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108127/efficacy-and-safety-of-trastuzumab-biosimilars-and-pertuzumab-biosimilars-combined-with-chemotherapy-for-neoadjuvant-treatment-of-patients-with-locally-advanced-her2-positive-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/explorando-la-duracion-del-tratamiento-con-terapia-neoadyuvante-anti-pd-1-en-el-cancer-colorrectal-en-estadio-ii-iii-con-dmmr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/exploring-the-treatment-duration-of-pd-1-neoadjuvant-therapy-in-stage-ii-iii-dmmr-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06577194/un-estudio-de-un-solo-centro-de-un-solo-brazo-sobre-radioterapia-neoadyuvante-de-curso-corto-con-il-2-seguida-de-inmunoterapia-secuencial-con-capox-combinada-con-un-anticuerpo-anti-pd-1-e-il-2-para 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06577194/neoadjuvant-short-course-radiotherapy-followed-by-capox-plus-pd-1-antibody-and-il-2-in-locally-advanced-rectal-cancer-pride01 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05378919/terapia-neoadyuvante-frente-a-terapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05378919/neoadjuvant-therapy-vs-standard-therapy-in-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05463796/inadvance-vigilancia-prevencion-e-intervencion-en-una-poblacion-con-riesgo-de-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05463796/inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04007770/estudio-piloto-sobre-la-acupuntura-para-la-funcion-cognitiva-relacionada-con-el-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04007770/acupuncture-pilot-study-for-cancer-related-cognitive-function 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714318/smarter-utilizando-muestras-de-sangre-para-mejorar-el-cribado-del-cancer-colorrectal-basado-en-la-prueba-fit 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714318/smarter-using-blood-samples-to-improve-fit-based-colorectal-cancer-screening 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07310446/recopilacion-de-muestras-de-la-poblacion-de-los-estados-unidos-para-la-optimizacion-y-evaluacion-del-rendimiento-del-panel-de-biomarcadores-de-adn-libre-circulante-en-plasma-cfdna-para-el-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310446/collection-of-samples-from-the-united-states-population-for-optimization-and-evaluation-of-colorectal-cancer-crc-plasma-circulating-free-dna-cfdna-marker-panel-performance 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07740720/un-estudio-sobre-la-duracion-del-tratamiento-con-dostarlimab-en-pacientes-no-tratados-con-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-desajustes-dmmr-y-alta 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740720/a-study-of-the-duration-of-dostarlimab-in-untreated-mismatch-repair-deficient-dmmr-microsatellite-instability-high-msi-h-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01060371/estudio-de-la-historia-natural-y-de-los-modificadores-geneticos-en-las-ataxias-espinocerebelosas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01060371/natural-history-study-of-and-genetic-modifiers-in-spinocerebellar-ataxias 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547385/estudio-de-ono-4578-y-xelox-folfox-mas-bevacizumab-en-el-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06547385/study-of-ono-4578-and-xelox-folfox-plus-bevacizumab-in-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/jovenes-adultos-con-canceres-gastrointestinales-y-neuroendocrinos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07254910/viabilidad-de-una-intervencion-multicanal-para-promover-la-deteccion-del-cancer-colorrectal-entre-los-nativos-americanos-de-oklahoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07254910/feasibility-of-a-multi-channel-intervention-to-promote-colorectal-cancer-screening-among-american-indians-in-oklahoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07750158/zanzalintinib-en-monoterapia-o-en-combinacion-con-pembrolizumab-y-berahyaluronidasa-alfa-en-participantes-con-cancer-colorrectal-con-enfermedad-residual-molecular 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07750158/zanzalintinib-alone-or-in-combination-with-pembrolizumab-and-berahyaluronidase-alfa-in-participants-with-colorectal-cancer-with-molecular-residual-disease 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07755124/privacion-dietetica-de-arginina-combinada-con-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-un-ensayo-clinico-aleatorizado-y-controlado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07755124/dietary-arginine-deprivation-combined-with-chemoradiotherapy-for-neoadjuvant-treatment-of-rectal-cancer-a-randomized-controlled-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05239546/estudio-de-un-solo-brazo-que-evalua-el-uso-de-dostarlimab-como-tratamiento-neoadyuvante-en-cancer-de-colon-en-estadio-ii-y-iii-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-dmmr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05239546/single-arm-study-of-neoadjuvant-dostarlimab-in-stage-ii-and-iii-deficient-mismatch-repair-colon-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528937/aplicacion-de-la-reconstruccion-tridimensional-para-la-planificacion-preoperatoria-del-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528937/application-of-3d-reconstruction-for-preoperative-strategy-of-locally-advanced-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07775287/estudio-de-petosemtamab-mas-quimioterapia-frente-a-cetuximab-o-bevacizumab-mas-quimioterapia-en-pacientes-con-cancer-colorrectal-recurrente-irresecable-o-metastasico-con-mutaciones-ras-y-braf-de-tipo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07775287/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-or-bevacizumab-plus-chemotherapy-in-ras-and-braf-wild-type-recurrent-unresectable-or-metastatic-colorectal-cancer-liger-crc2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07775950/investigacion-sobre-el-seguimiento-de-la-recurrencia-del-cancer-colorrectal-y-el-tratamiento-individualizado-basado-en-la-enfermedad-residual-minima-erm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07775950/research-on-colorectal-cancer-recurrence-monitoring-and-individualized-treatment-based-on-mrd 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07779694/ayuno-de-16-horas-mas-serplulimab-y-capeox-como-terapia-neoadyuvante-en-cancer-colorrectal-avanzado-de-localizacion-media-a-baja-con-pmmr-mss 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07779694/16-hour-fasting-plus-serplulimab-and-capeox-as-neoadjuvant-therapy-in-pmmr-mss-advanced-mid-to-low-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07346534/anastomosis-reforzada-frente-a-anastomosis-convencional-en-la-reseccion-laparoscopica-de-cancer-de-recto-bajo-un-estudio-comparativo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07346534/reinforced-versus-conventional-anastomosis-in-laparoscopic-low-rectal-cancer-resection-a-comparative-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07345676/programa-de-divulgacion-para-la-deteccion-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07345676/colorectal-cancer-screening-outreach 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06700317/imagenologia-hiperespectral-intraoperatoria-para-la-cirugia-laparoscopica 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06700317/intraoperative-hyperspectral-imaging-for-laparoscopic-surgery 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05994482/colonoscopia-de-vigilancia-en-adultos-mayores-el-estudio-survolderadults 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05994482/surveillance-colonoscopy-in-older-adults-the-survolderadults-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975491/el-ensayo-clinico-sobre-el-ejercicio-y-el-tratamiento-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975491/the-exercise-and-colorectal-cancer-treatment-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06017583/quimioterapia-neoadyuvante-con-inhibidores-de-pd-1-combinada-con-sib-imrt-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/neoadjuvant-chemotherapy-with-pd-1-inhibitors-combined-with-sib-imrt-in-the-treatment-of-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-penpulimab-en-combinacion-con-capeox-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-sequential-penpulimab-in-combination-with-capeox-in-the-neoadjuvant-treatment-of-mss-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/estudio-de-eficacia-y-seguridad-de-tisotumab-vedotina-en-pacientes-con-tumores-solidos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/efficacy-and-safety-study-of-tisotumab-vedotin-for-patients-with-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06850103/scrt-capeox-serplulimab-para-el-cancer-colorrectal-mss-pmmr-con-oligometastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06850103/scrt-capeox-serplulimab-for-mss-pmmr-rectal-cancer-with-oligometastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05699746/capeox-frente-a-observacion-en-pacientes-con-cancer-colorrectal-y-enfermedad-residual-detectable-mrd-positiva 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05699746/capeox-vs-observation-in-colorectal-cancer-patients-with-positive-mrd 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-mas-cetuximab-en-un-entorno-neoadyuvante-en-pacientes-con-cancer-de-colon-o-recto-superior-localizado-con-mutacion-braf 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-plus-cetuximab-in-a-neoadjuvant-setting-in-patients-with-braf-mutation-localised-colon-or-upper-rectum-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06751966/vacuna-peptidica-basada-en-neoantigenos-y-terapia-convencional-de-tercera-linea-para-el-ccrc-que-progresa-tras-el-tratamiento-de-segunda-linea 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06751966/neoantigen-based-peptide-vaccine-and-conventional-third-line-therapy-for-crc-progressed-after-second-line-treatment 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07090304/ensayo-chino-sobre-la-deteccion-del-cancer-colorrectal-2-c-cost2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07090304/china-colorectal-cancer-screening-trial-2-c-cost2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03926338/toripalimab-como-tratamiento-neoadyuvante-con-o-sin-celecoxib-en-cancer-colorrectal-con-dmmr-msi-h 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/neoadjuvant-toripalimab-with-or-without-celecoxib-in-dmmr-msi-h-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05346757/validacion-de-un-test-fecal-basado-en-microarn-mirfec-para-el-cribado-la-vigilancia-y-el-diagnostico-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05346757/validation-of-a-microrna-based-fecal-mirfec-test-for-colorectal-cancer-screening-surveillance-and-diagnosis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682650/implementacion-de-una-herramienta-de-deteccion-del-cancer-colorrectal-en-centros-de-atencion-primaria-de-los-estados-unidos-mejora-de-la-calidad-habitual-10-centros-frente-al-proceso-de-normalizacion 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682650/implementation-of-a-colorectal-cancer-screening-tool-in-us-primary-care-practices-usual-quality-improvement-10-clinics-vs-normalization-process-theory-participatory-learning-in-action-10-clinics 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/evaluacion-de-la-fragilidad-y-sus-efectos-en-pacientes-que-se-someten-a-una-cirugia-mayor-del-tracto-gastrointestinal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/assessing-frailty-and-its-impacts-on-patients-facing-major-gi-surgery 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03955510/alteraciones-en-los-horarios-de-las-comidas-y-disincronia-circadiana-en-la-carcinogenesis-del-colon-inducida-por-el-alcohol 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03955510/abnormal-food-timing-and-circadian-dyssynchrony-in-alcohol-induced-colon-carcinogenesis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05841134/tislelizumab-en-combinacion-con-quimioterapia-capox-en-el-tratamiento-perioperatorio-del-cancer-colorrectal-en-estadio-ii-o-iii-con-msi-h-dmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05841134/tislelizumab-combined-with-chemotherapy-capox-in-the-perioperative-treatment-of-msi-h-dmmr-stage-ii-or-iii-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02000089/el-estudio-caps5-cancer-of-the-pancreas-screening-5 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02000089/the-cancer-of-the-pancreas-screening-5-caps5-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06304545/tratamiento-del-cancer-de-recto-con-quimiorradioterapia-concurrente-a-largo-plazo-combinada-con-camrelizumab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/treatment-of-rectal-cancer-with-long-term-concurrent-chemoradiotherapy-combined-with-camrelizumab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06838546/un-estudio-clinico-multicentrico-abierto-de-fase-iib-para-evaluar-la-eficacia-y-la-seguridad-de-la-inyeccion-de-b1962-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838546/a-multicenter-open-phase-iib-clinical-study-to-evaluate-the-efficacy-and-safety-of-b1962-injection-in-the-treatment-of-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04339374/ecografia-e-imagen-fotoacustica-para-mejorar-el-diagnostico-diferencial-del-cancer-de-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04339374/ultrasound-and-photoacoustic-imaging-for-enhanced-differential-diagnosis-of-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-en-combinacion-con-los-regimenes-folfox-folfiri-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-combined-with-folfox-folfiri-regimen-in-patients-with-advanced-colorectal-liver-metastases-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674422/estudio-gemcad-reveal-el-adn-tumoral-circulante-como-predictor-de-recurrencia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/gemcad-reveal-study-circulating-tumor-dna-as-a-predictor-of-relapse-in-patients-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-mas-cetuximab-y-quimioterapia-con-folfox-para-el-cancer-colorrectal-metastasico-con-mutacion-ras-braf-silvestre 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-plus-cetuximab-and-folfox-chemotherapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07198321/un-estudio-clinico-de-fase-i-ii-abierto-multicentrico-y-de-un-solo-brazo-para-evaluar-el-farmaco-gfh276-en-pacientes-con-tumores-solidos-avanzados-con-mutaciones-en-el-gen-ras 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198321/a-single-arm-open-label-multicenter-phase-i-ii-clinical-study-of-gfh276-in-patients-with-ras-mutant-advanced-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05174286/trabajadores-comunitarios-de-la-salud-unidos-para-reducir-el-cancer-colorrectal-y-las-enfermedades-cardiovasculares-en-personas-con-mayor-riesgo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05174286/community-health-workers-united-to-reduce-colorectal-cancer-and-cardiovascular-disease-among-people-at-higher-risk 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07696169/evolucion-de-la-enfermedad-y-factores-de-riesgo-de-los-canceres-prevalentes-relacionados-con-el-sida 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07696169/disease-evolution-and-risk-factors-of-aids-related-prevalent-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05605353/aprovechando-el-potencial-del-microbioma-intestinal-y-sus-metabolitos-en-el-cancer-pelvico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05605353/exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/se-anade-epacadostat-incb024360-a-la-quimiorradiacion-preoperatoria-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/epacadostat-incb024360-added-to-preoperative-chemoradiation-in-patients-with-locally-advanced-rectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07168876/investigacion-sobre-la-biopsia-liquida-en-el-cancer-de-colon-evaluacion-de-biomarcadores-basados-en-la-metilacion-mediante-delta-hld-climbed 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07168876/colon-cancer-liquid-biopsy-investigation-of-methylation-based-biomarkers-evaluation-using-delta-hld-climbed 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/estudio-de-xl092-atezolizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/study-of-xl092-atezolizumab-vs-regorafenib-in-participants-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/resistencia-primaria-y-adquirida-al-tratamiento-dirigido-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/primary-and-acquired-resistance-to-targeted-treatment-in-braf-v600e-mutated-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-y-panitumumab-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-and-panitumumab-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-en-pacientes-con-crc-sometidos-a-cirugia-con-intencion-curativa-para-metastasis-hepaticas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-in-crc-patients-undergoing-curative-intent-surgery-for-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031570/eficacia-y-seguridad-de-la-combinacion-de-deb-tace-con-haic-frente-a-haic-sola-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031570/efficacy-and-safety-of-deb-tace-combined-with-haic-versus-haic-alone-in-patients-with-unresectable-crlm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04188145/un-estudio-aleatorizado-de-fase-iii-que-compara-el-tratamiento-de-mantenimiento-con-fluoropirimidina-bevacizumab-frente-a-fluoropirimidina-despues-de-la-quimioterapia-de-induccion-en-pacientes-con 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-after-induction-chemotherapy-for-a-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06282445/eficacia-y-seguridad-de-la-quimioterapia-con-xelox-oxaliplatino-capecitabina-y-bevacizumab-en-combinacion-con-adebrelimab-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06282445/efficacy-and-safety-of-chemotherapy-with-xelox-oxaliplatin-capecitabine-and-bevacizumab-in-combination-with-adebrelimab-in-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06287723/estudio-frances-sobre-la-evaluacion-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-french-mrd-crlm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287723/french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-french-mrd-crlm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomida-y-bevacizumab-para-el-cancer-colorrectal-metastasico-con-metilacion-del-gen-mgmt-y-estabilidad-de-microsatelites 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomide-and-bevacizumab-for-mgmt-silenced-microsatellite-stable-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/individualizacion-de-la-dosis-de-quimioterapia-en-pacientes-con-canceres-gastrointestinales-que-carecen-de-una-enzima-hepatica-especifica 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/dose-individualization-of-chemotherapy-in-patients-with-gastrointestinal-cancers-lacking-a-specific-liver-enzyme 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-en-combinacion-con-fruquintinib-en-el-tratamiento-de-la-amplificacion-de-met-o-la-sobreexpresion-de-la-proteina-en-el-cancer-colorrectal-metastasico-irresecable-en-tercera-linea-de 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980532/glumetinib-combined-with-fruquintinib-in-the-treatment-of-met-amplification-or-protein-overexpression-in-third-line-unresectable-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02394834/un-estudio-exploratorio-de-la-sensibilidad-al-tratamiento-y-los-factores-pronosticos-en-un-estudio-de-eficacia-y-seguridad-de-mfolfox6-bevacizumab-frente-a-mfolfox6-panitumumab-en-pacientes-con 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/an-exploratory-study-of-treatment-sensitivity-and-prognostic-factors-in-a-efficacy-and-safety-study-of-mfolfox6-bevacizumab-versus-mfolfox6-panitumumab-therapy-in-patients-with-chemotherapy-naive 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-alcestobart-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/dat-2645-un-inhibidor-de-parg-como-monoterapia-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-alteraciones-de-perdida-de-funcion-en-brca1-2-y-o-otros-defectos-en-la-via-de 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/a-parg-inhibitor-dat-2645-monotherapy-in-patients-with-advanced-metastatic-solid-tumors-harboring-brca1-2-loss-of-function-alterations-and-or-other-defects-in-the-ddr-pathway 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911970/impacto-del-ejercicio-aerobico-en-la-respuesta-inmune-antitumoral-en-pacientes-que-reciben-tratamiento-contra-el-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911970/impact-of-aerobic-exercise-on-the-anticancer-immune-response-in-patients-receiving-cancer-treatment 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134205/estudio-de-jmt101-en-combinacion-con-irinotecan-como-tratamiento-en-3a-linea-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134205/the-study-of-jmt101-combined-with-irinotecan-as-a-3rd-line-treatment-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/ensayo-clinico-sobre-celulas-tumorales-circulantes-en-cancer-de-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/rectal-cancer-ctc-trial 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05129787/ablacion-frente-a-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablation-vs-resection-of-colorectal-cancer-liver-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856187/tratamiento-estandar-de-segunda-linea-tratamiento-secuencial-con-tas-102-y-bevacizumab-combinado-con-tratamiento-local-en-cancer-colorrectal-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/second-line-standard-treatment-sequential-tas-102-and-bevacizumab-combined-with-local-treatment-in-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnostico-de-multiples-tipos-de-cancer-y-seguimiento-de-tumores-residuales-minimos-tras-el-tratamiento-mediante-el-analisis-de-sangre-y-tecnicas-geneticas-de-alta-sensibilidad 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06411600/terapia-combinada-para-el-crcm-metastasico-con-mutacion-braf-v600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06411600/combination-therapy-for-braf-v600e-metastatic-crcm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698146/metastasis-colorrectal-en-el-higado-extraccion-con-trasplante-auxiliar-y-reseccion-tardia 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698146/colorectal-metastasis-to-liver-extraction-with-auxiliary-transplant-and-delayed-resection 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-protocolo-del-estudio-clinico-de-rendimiento-para-el-kit-therascreen-r-kras-rgq-pcr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-clinical-performance-study-protocol-for-therascreen-r-kras-rgq-pcr-kit 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/ensayo-internacional-sobre-la-prevencion-de-metastasis-del-cancer-colorrectal-2 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/colorectal-metastasis-prevention-international-trial-2 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/estrategias-de-prevencion-cardiovascular-en-pacientes-oncologicos-de-edad-avanzada-ensayo-clinico-cartier 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/caracterizacion-molecular-de-las-metastasis-peritoneales-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/molecular-characterisation-of-colorectal-cancer-peritoneal-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/un-estudio-de-fruquintinib-mas-folfiri-como-tratamiento-de-segunda-linea-para-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05797077/terapia-de-mantenimiento-postoperatoria-para-metastasis-hepaticas-resecables-del-cancer-colorrectal-guiada-por-ctdna 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07079462/comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/estudio-de-cohorte-prospectivo-sobre-la-relacion-entre-la-peroxiredoxina-1-exosomal-prdx1-y-la-metastasis-hepatica-postoperatoria 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluacion-de-rbs2418-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-y-en-progresion 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluation-of-rbs2418-in-patients-with-advanced-metastatic-and-progressive-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06889610/un-estudio-clinico-de-fase-ii-sobre-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06889610/a-phase-ii-clinical-study-of-multimodal-ablation-combined-with-systemic-drug-therapy-for-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04714957/pitcher-heterogeneidad-de-la-carcinomatosis-peritoneal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04714957/pitcher-peritoneal-carcinomatosis-heterogeneity 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-en-combinacion-con-tas-102-y-bevacizumab-en-el-cancer-colorrectal-recurrente-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-in-combination-with-tas-102-and-bevacizumab-in-recurrent-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparacion-de-chidamide-sintilimab-bevacizumab-con-el-regimen-estandar-de-segunda-linea-folfiri-bevacizumab-en-pacientes-con-mcrc-avanzado-mss-pmmr 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparing-chidamide-sintilimab-bev-with-standard-second-line-folfiri-bev-in-advanced-mss-pmmr-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/lyl273-for-patients-with-relapsed-or-refractory-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/un-estudio-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-comparativo-de-fase-iii-para-evaluar-la-eficacia-y-la-seguridad-de-las-capsulas-de-nuvastatic-r-de-300-mg-en-la 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-r-300mg-capsule-in-reducing-cancer-tumor-in-patients-with 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoinmunomodulacion-antes-de-la-cirugia-en-el-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoimmunomodulation-before-leveraging-excision-in-colorectal-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150247/seguridad-y-eficacia-de-ib-folfiri-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150247/safety-and-efficacy-of-ib-folfiri-in-braf-v600e-mutant-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/panitumumab-administrado-de-forma-intermitente-o-continua-en-combinacion-con-folfiri-para-el-cancer-colorrectal-metastasico-de-lado-izquierdo-con-mutaciones-ras-b-raf-de-tipo-salvaje 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/intermittent-or-continuous-panitumumab-plus-folfiri-for-left-sided-ras-b-raf-wild-type-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150403/quimioterapia-combinada-de-segunda-linea-folfox-o-folfiri-mas-fruquintinib-frente-a-quimioterapia-combinada-folfox-o-folfiri-mas-bevacizumab-en-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/second-line-doublet-chemotherapy-folfox-or-folfiri-plus-fruquintinib-versus-doublet-chemotherapy-folfox-or-folfiri-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04867525/plataforma-de-registro-de-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04867525/registry-platform-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05771181/vitamina-e-en-combinacion-con-fruquintinib-y-tislelizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05771181/vitamin-e-combined-with-fruquintinib-and-tislelizumab-in-microsatellite-stabilized-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/cinetica-de-eliminacion-del-nucleosoma-y-ctcf-en-sangre-en-el-cancer-colorrectal-con-metastasis-peritoneales 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/blood-clearance-kinetics-of-the-nucleosome-and-ctcf-in-peritoneal-metastasis-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-en-combinacion-en-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-en-estadio-iv-resistente-al-tratamiento-y-en-otros-canceres-metastasicos-del 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-combination-in-stage-iv-refractory-pmmr-mss-crc-and-other-metastatic-gi-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-frente-a-bevacizumab-en-combinacion-con-irinotecan-liposomal-y-capecitabina-como-terapia-de-segunda-linea-para-el-cancer-colorrectal-metastasico-avanzado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-vs-bevacizumab-combined-with-irinotecan-liposome-and-capecitabine-as-second-line-therapy-for-advanced-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/estudio-de-fuquinitinib-en-combinacion-con-capecitabina-como-tratamiento-de-mantenimiento-de-primera-linea-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/study-of-fuquinitinib-combined-with-capecitabine-first-line-maintenance-in-the-treatment-of-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/estudio-de-fase-i-ii-que-evalua-mcla-129-un-anticuerpo-humano-bispecifico-anti-egfr-y-anti-c-met-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-y-otros-tumores-solidos-tanto-en 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/phase-1-2-study-evaluating-mcla-129-a-human-anti-egfr-anti-c-met-bispecific-antibody-in-advanced-nsclc-and-other-solid-tumors-alone-and-in-combination 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07702032/estudio-de-petosemtamab-mas-quimioterapia-frente-a-cetuximab-mas-quimioterapia-en-cancer-colorrectal-irresecable-o-metastasico-del-lado-izquierdo-con-ras-y-braf-de-tipo-salvaje 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07702032/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-plus-chemotherapy-in-ras-and-braf-wild-type-unresectable-or-metastatic-left-sided-colorectal-cancer-liger-crc1 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/inhibidores-de-los-puntos-de-control-inmunitario-para-la-preservacion-de-organos-en-canceres-gastricos-o-de-colon-no-metastasicos-con-dmmr-msi-h 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmr-msi-h-gastric-or-colon-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/modelado-personalizado-de-xenoinjertos-derivados-del-paciente-ppdx-para-evaluar-la-respuesta-a-farmacos-en-un-huesped-compatible 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/personalized-patient-derived-xenograft-ppdx-modeling-to-test-drug-response-in-matching-host 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/adn-circulante-para-mejorar-el-pronostico-de-los-pacientes-oncologicos-un-estudio-aleatorizado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258137/circulating-dna-to-improve-outcome-of-oncology-patient-a-randomized-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03401294/conversion-de-cancer-colorrectal-metastasico-irresecable-a-resecable 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07714447/eficacia-y-seguridad-de-la-terapia-combinada-con-tunlametinib-en-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treatment-of-second-line-and-above-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-y-pembrolizumab-mk3475-en-el-tratamiento-del-mcrc-y-el-nsclc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07718490/inmunoterapia-combinada-con-simvastatina-y-terapia-dirigida-y-quimioterapia-para-el-cancer-colorrectal-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07718490/immunotheray-combined-with-simvastatin-and-target-therapy-and-chemotharepy-for-advanced-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/un-estudio-de-fase-ii-de-ssgj-707-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/un-ensayo-de-fase-i-iia-fih-que-evalua-la-viabilidad-de-la-administracion-de-inmunoterapia-basada-en-til-en-pacientes-con-crc-metastasico-y-cancer-de-pancreas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/a-fih-phase-i-iia-trial-assessing-feasibility-of-administrations-of-til-based-immunotherapy-in-patients-with-metastatic-crc-and-pc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05239650/estudio-clinico-de-fase-ii-para-evaluar-la-eficacia-y-la-seguridad-de-hlx07-hlx10-mfolfox6-o-hlx07-en-monoterapia-en-pacientes-con-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05239650/phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-hlx07-hlx10-mfolfox6-or-hlx07-monotherapy-in-patients-with-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-en-combinacion-con-fianlimab-para-el-cancer-colorrectal-no-metastasico-que-puede-ser-extirpado-quirurgicamente 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-with-fianlimab-for-resectable-non-metastatic-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555003/quimioterapia-con-debiri-mas-otros-farmacos-frente-a-quimioterapia-sola-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555003/debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07744139/perfilado-radiogenomico-de-las-celulas-dendriticas-y-los-macrofagos-para-predecir-la-recurrencia-en-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07744139/radiogenomic-profiling-of-dendritic-cells-and-macrophages-to-predict-recurrence-in-colorectal-liver-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07752875/un-estudio-de-lg00313112-en-participantes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07752875/a-study-of-lg00313112-in-participants-with-advanced-solid-malignancies-harboring-a-tp53-y220c-mutation 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/radioterapia-ultrafraccionada-guiada-por-cga-y-tratamiento-sistemico-de-primera-linea-en-pacientes-ancianos-o-fragiles-con-cmmr 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/cga-guided-ultrafractionated-rt-and-first-line-systemic-treatment-in-elderly-or-frail-patients-with-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06907342/evaluacion-de-un-enfoque-de-medicina-de-precision-funcional-para-seleccionar-la-quimioterapia-en-el-cancer-colorrectal-metastasico-cosense-1 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/testing-a-functional-precision-medicine-approach-to-select-chemotherapy-for-metastatic-colorectal-cancer-cosense-1 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06654037/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-abemaciclib-al-tratamiento-quimioterapeutico-habitual-5-fluorouracilo-para-el-cancer-colorrectal-metastasico-y-refractario 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/testing-the-addition-of-an-anti-cancer-drug-abemaciclib-to-the-usual-chemotherapy-treatment-5-fluorouracil-for-metastatic-refractory-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01815359/icarus-quimioterapia-intraperitoneal-postoperatoria-epic-y-quimioterapia-intraperitoneal-hiperermica-hipec-tras-una-cirugia-citoreductora-optima-crs-para-neoplasias-del-apendice-colon-o-recto-con 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01815359/icarus-post-operative-intraperitoneal-chemotherapy-epic-and-hyperthermic-intraperitoneal-chemotherapy-hipec-after-optimal-cytoreductive-surgery-crs-for-neoplasms-of-the-appendix-colon-or-rectum-with 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-en-combinacion-con-adebrelimab-y-radioterapia-en-dosis-altas-y-bajas-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mss-que-ha-progresado-tras-tratamientos-previos-segunda 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-combined-with-adebrelimab-and-high-and-low-dose-radiotherapy-in-the-treatment-of-second-line-and-above-failure-mss-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03451370/tratamiento-de-primera-linea-con-la-combinacion-de-capecitabina-y-oxaliplatino-mas-bevacizumab-en-pacientes-ancianos-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03451370/first-line-combination-of-capecitabine-and-oxaliplatin-plus-bevacizumab-in-elderly-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07540572/un-estudio-para-investigar-la-seguridad-la-farmacocinetica-y-la-eficacia-preliminar-de-la-terapia-con-ide574-en-participantes-adultos-con-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07540572/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-ide574-therapy-in-adult-participants-with-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154173/analisis-exhaustivo-de-las-caracteristicas-de-la-microbiota-intestinal-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154173/comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-colorrectal-metastasico-en-estadio-iv-susceptible-de-reseccion-surveillance-ii 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/mrd-guided-surveillance-in-resectable-stage-iv-metastatic-colorectal-cancer-surveillance-ii 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07353268/estudio-de-fase-ib-ii-de-ql1706-fruquintinib-terapia-de-radiacion-concurrente-scrt-frente-a-la-terapia-estandar-de-tercera-linea-en-cancer-colorrectal-irresecable-con-metastasis-hepaticas-y-estado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07353268/phase-ib-ii-study-of-ql1706-fruquintinib-scrt-vs-standard-third-line-therapy-in-unresectable-liver-metastatic-pmmr-mss-colorectal-cancer-safety-tolerability-and-efficacy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595957/programa-de-investigacion-en-servicios-genomicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595957/genomic-services-research-program 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05884723/dieta-cetogenica-preoperatoria-para-la-reduccion-de-la-esteatosis-hepatica 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05884723/preoperative-ketogenic-diet-for-reduction-of-hepatic-steatosis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluacion-de-una-prueba-diagnostica-para-identificar-los-mejores-farmacos-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluation-of-a-diagnostic-test-to-identify-the-best-drugs-for-treatment-of-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381309/virus-oncolitico-h101-radioterapia-estereotactica-ablativa-sbrt-quimioterapia-terapia-dirigida-inmunoterapia-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/oncolytic-virus-h101-sbrt-chemotherapy-targeted-therapy-immunotherapy-for-unresectable-crlm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-en-combinacion-con-quimioterapia-metronomica-multimodal-para-cancer-colorrectal-metastasico-resistente-a-la-quimioterapia 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-in-combination-with-multimodal-metronomic-chemotherapy-for-chemo-resistant-metastatic-colorectal-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208397/resonancia-magnetica-para-la-evaluacion-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/viabilidad-tecnica-de-la-quimioterapia-intraperitoneal-modificada-en-las-primeras-etapas-del-periodo-postoperatorio-mepic 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/technical-feasibility-of-modified-early-post-operative-intraperitoneal-chemotherapy-mepic 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03364621/analisis-genomico-exhaustivo-de-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-aisladas-para-comprender-la-respuesta-y-la-resistencia-a-la-terapia-contra-el-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/comprehensive-genomic-profiling-of-colorectal-cancer-patients-with-isolated-liver-metastases-to-understand-response-resistance-to-cancer-therapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/un-estudio-para-investigar-cea-prit-2-0-en-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-colorectal-cancer-mcrc 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/ensayo-sobre-la-aplicacion-integrada-de-la-elaboracion-de-perfiles-moleculares-en-canceres-avanzados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/integrated-molecular-profiling-in-advanced-cancers-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05863195/evaluacion-de-la-quimioterapia-con-bomba-de-infusion-como-complemento-a-la-quimioterapia-estandar-en-comparacion-con-la-quimioterapia-estandar-sola-en-pacientes-con-metastasis-hepaticas-irresecables 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05863195/testing-pump-chemotherapy-in-addition-to-standard-of-care-chemotherapy-versus-standard-of-care-chemotherapy-alone-for-patients-with-unresectable-colorectal-liver-metastases-the-pump-trial 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/eficacia-y-seguridad-de-ibi351-cetuximab-en-combinacion-con-folfiri-como-tratamiento-de-primera-linea-y-de-ibi351-cetuximab-como-tratamiento-de-segunda-linea-en-el-tratamiento-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/the-efficacy-and-safety-of-ibi351-cetuximab-combined-with-folfiri-as-first-line-ibi351-cetuximab-as-second-line-in-the-treatment-of-kras-g12c-mutated-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-mas-folfiri-en-segunda-linea-para-el-cancer-colorrectal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-plus-folfiri-in-second-line-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-regimen-estandar-de-quimioterapia-e-inmunoterapia-con-celulas-t-receptor-de-antigeno-quimerico-alogenicas-basadas-en-nkg2d-cyad-101 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-nkg2d-based-cyad-101-chimeric-antigen-receptor-t-cells 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-mas-bevacizumab-con-o-sin-atezolizumab-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-pmmr-e-ic-alto 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-plus-bevacizumab-with-or-without-atezolizumab-as-1st-line-treatment-of-pmmr-and-is-ic-high-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-en-combinacion-con-folfox-como-tratamiento-neoadyuvante-previo-a-la-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-combined-with-folfox-as-neoadjuvant-treatment-prior-to-resection-of-colorectal-cancer-liver-metastasis 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-en-combinacion-con-pemetrexed-para-el-tratamiento-de-tumores-solidos-metastasicos-con-delecion-de-mtap 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-in-combination-with-pemetrexed-for-the-treatment-of-metastatic-solid-tumors-with-mtap-deletion 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03844620/pruebas-de-adn-tumoral-libre-circulante-en-sangre-para-guiar-el-tratamiento-de-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT03844620/circulating-cell-free-tumor-dna-testing-in-guiding-treatment-for-patients-with-advanced-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-en-el-cancer-colorrectal-avanzado-un-estudio-exploratorio 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-in-advanced-colorectal-cancer-an-exploratory-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/estudio-de-jdq443-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/study-of-jdq443-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/un-estudio-de-fase-1-2-de-st316-en-pacientes-con-tumores-solidos-avanzados-irresecables-y-metastasicos-seleccionados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/a-phase-1-2-of-st316-with-selected-advanced-unresectable-and-metastatic-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284849/un-estudio-para-evaluar-la-eficacia-y-la-seguridad-de-la-quimioterapia-estandar-y-el-bevacizumab-con-o-sin-inca33890-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/un-estudio-de-shy-onc6-un-nuevo-inhibidor-del-proteasoma-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/a-study-of-shy-onc6-a-novel-proteasome-inhibitor-in-adults-with-advanced-or-metastatic-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07602504/base-de-datos-del-registro-clinico-chino-de-pacientes-con-cancer-de-higado-metastasico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/china-metastatic-liver-cancer-clinical-registry-cohort-database 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292298/estudio-de-fase-ii-ensayo-de-un-solo-brazo-sobre-braquiterapia-en-pacientes-con-cancer-de-recto-y-adenocarcinoma-residual-localizado-en-la-parte-inferior-tras-la-terapia-neoadyuvante-total-con-el 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292298/phase-2-single-arm-rectal-cancer-brachytherapy-for-patients-with-low-lying-residual-adenocarcinoma-after-total-neoadjuvant-therapy-to-improve-organ-preservation-rates 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07715903/infusion-intraarterial-hepatica-de-carfilzomib-en-participantes-con-enfermedad-metastasica-hepatica-que-previamente-recibieron-tratamiento-con-bomba-de-infusion-intraarterial-hepatica 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07715903/hepatic-artery-infusion-of-carfilzomib-in-participants-with-liver-metastatic-disease-previously-treated-with-hepatic-artery-infusion-pump-therapy 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07488676/un-estudio-de-asp546c-en-adultos-con-cancer-gastroesofagico-cancer-de-pancreas-u-otros-tumores-solidos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07488676/a-study-of-asp546c-in-adults-with-gastroesophageal-cancer-pancreatic-cancer-or-other-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04421820/bold-100-en-combinacion-con-folfox-para-el-tratamiento-de-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04421820/bold-100-in-combination-with-folfox-for-the-treatment-of-advanced-solid-tumours 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02688712/estudio-exist-de-ly2157299-galunisertib-en-cancer-de-recto 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02688712/exist-study-of-ly2157299-galunisertib-in-rectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04147494/estudios-experimentales-con-tomografias-por-emision-de-positrones-pet-realizadas-antes-de-la-cirugia-del-cancer-para-analizar-la-cantidad-de-trazador-pet-acumulado-en-los-tejidos-normales-y-cancerosos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04147494/experimental-pet-imaging-scans-before-cancer-surgery-to-study-the-amount-of-pet-tracer-accumulated-in-normal-and-cancer-tissues 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06586515/moonray-01-un-estudio-de-ly3962673-en-participantes-con-tumores-solidos-con-mutacion-kras-g12d 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06586515/moonray-01-a-study-of-ly3962673-in-participants-with-kras-g12d-mutant-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07610798/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-preliminar-de-inv-8989-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-kras-g12d 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07610798/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity-of-inv-8989-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutations 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06638931/terapia-agnostica-en-tumores-solidos-poco-frecuentes 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06638931/agnostic-therapy-in-rare-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943820/terapia-combinada-con-ak129-para-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943820/ak129-combination-therapy-for-advanced-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-mas-durvalumab-con-o-sin-tremelimumab-en-pacientes-con-cancer-gastroesofagico-y-otras-neoplasias-gastrointestinales 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-plus-durvalumab-with-or-without-tremelimumab-in-patients-with-gastroesophageal-cancer-and-other-gastrointestinal-malignancies 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117945/regorafenib-en-combinacion-con-cetuximab-o-panitumumab-para-el-tratamiento-del-cancer-colorrectal-no-operable-localmente-avanzado-o-metastasico 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04117945/regorafenib-with-cetuximab-or-panitumumab-for-the-treatment-of-unresectable-locally-advanced-or-metastatic-colorectal-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05651022/estudio-de-decoy20-con-o-sin-tislelizumab-en-pacientes-con-tumores-solidos-avanzados 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05651022/study-of-decoy20-with-or-without-tislelizumab-in-patients-with-advanced-solid-tumors 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07620574/estudio-de-extension-a-largo-plazo-para-participantes-que-ya-participaron-en-un-estudio-patrocinado-por-exelixis 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07620574/long-term-extension-study-for-participants-previously-enrolled-in-an-exelixis-sponsored-study 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT05443087/monitorizacion-de-la-terapia-dirigida-con-farmacos-en-la-oncologia-digestiva 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05443087/targeted-therapy-drug-monitoring-in-digestive-oncology 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05059444/oracle-observacion-de-enfermedad-residual-mediante-evaluacion-con-biopsia-liquida 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05059444/oracle-observation-of-residual-cancer-with-liquid-biopsy-evaluation 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/un-enfoque-terapeutico-multimodal-personalizado-integrado-y-adaptado-al-estadio-a-nivel-mundial-para-el-adenocarcinoma-rectal-basado-en-la-preservacion-de-organos-y-la-minima-invasion 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/un-estudio-para-evaluar-la-seguridad-y-la-actividad-terapeutica-de-gi-102-como-agente-unico-y-en-combinacion-con-farmacos-antineoplasicos-convencionales-pembrolizumab-o-trastuzumab-deruxtecan-t-dxd 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/a-study-to-evaluate-the-safety-and-therapeutic-activity-of-gi-102-as-a-single-agent-and-in-combination-with-conventional-anti-cancer-drugs-pembrolizumab-or-trastuzumab-deruxtecan-t-dxd-in-patients 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07145255/estudio-de-fase-i-ii-para-determinar-la-dosis-evaluar-la-seguridad-y-la-farmacocinetica-en-tumores-solidos-avanzados-y-refractarios 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07145255/phase-1-2-dose-finding-safety-and-pk-study-in-advanced-refractory-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04535401/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-bay-1895344-a-la-quimioterapia-estandar-con-folfiri-en-canceres-avanzados-o-metastasicos-del-estomago-e-intestinos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04535401/testing-the-addition-of-an-anticancer-drug-bay-1895344-to-the-usual-chemotherapy-with-folfiri-in-advanced-or-metastatic-cancers-of-the-stomach-and-intestines 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT07082439/pembrolizumab-y-odetiglucano-en-el-adenocarcinoma-colorrectal-metastasico-con-predominio-hepatico 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT07082439/pembrolizumab-and-odetiglucan-in-liver-predominant-metastatic-colorectal-adenocarcinoma 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008797/un-estudio-de-e7386-en-combinacion-con-otros-farmacos-antineoplasicos-en-participantes-con-tumores-solidos 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008797/a-study-of-e7386-in-combination-with-other-anticancer-drug-s-in-participants-with-solid-tumor 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06447662/un-estudio-para-evaluar-el-medicamento-pf-07934040-administrado-solo-o-en-combinacion-con-otras-terapias-contra-el-cancer-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-genetica 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT06447662/a-study-to-learn-about-the-study-medicine-pf-07934040-when-given-alone-or-with-other-anti-cancer-therapies-in-people-with-advanced-solid-tumors-that-have-a-genetic-mutation 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-en-combinacion-con-ataluren-en-pacientes-con-carcinoma-colorrectal-metastasico-pmmr-y-dmmr-o-carcinoma-endometrial-metastasico-dmmr-el-estudio-atapembro 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-with-ataluren-in-patients-with-metastatic-pmmr-and-dmmr-colorectal-carcinoma-or-metastatic-dmmr-endometrial-carcinoma-the-atapembro-study 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/estudio-de-jyp0015-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-especificas-en-ras 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06995898/el-estudio-vanguard-evaluacion-de-una-nueva-forma-de-deteccion-del-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT06995898/the-vanguard-study-testing-a-new-way-to-screen-for-cancer 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05919264/fog-001-en-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05919264/fog-001-in-locally-advanced-or-metastatic-solid-tumors 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05272709/tt-702-en-pacientes-con-tumores-solidos-avanzados 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT05272709/tt-702-in-patients-with-advanced-solid-tumours 2026-08-26 weekly 0.7 https://crcwarriors.org/ensayo/NCT02293954/el-uso-del-anticuerpo-monoclonal-marcado-con-cobre-64-cu-64-anti-cea-m5a-en-la-tomografia-por-emision-de-positrones-pet-para-el-diagnostico-de-pacientes-con-cancer-cea-positivo 2026-08-26 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/copper-cu-64-anti-cea-monoclonal-antibody-m5a-pet-in-diagnosing-patients-with-cea-positive-cancer 2026-08-26 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-08-22 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-08-22 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-08-18 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-08-18 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-08-20 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-08-20 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-08-01 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-08-01 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mrg007 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/mrg007/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2975/un-estudio-multicentrico-sobre-el-cribado-de-braf-para-la-implementacion-de-la-genomica-perioperatoria-en-el-tratamiento-de-las-metastasis-oligo-metastasicas-resecables-del-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2975/a-multicenter-survey-on-braf-screening-for-the-implementation-of-perioperative-cancer-genomic-medicine-for-resectable-colorectal-oligometastases 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2969/ifebemtinib-mas-garsorasib-en-el-cancer-colorrectal-metastasico-con-mutacion-kras-g12c-previamente-tratado-un-ensayo-multicentrico-aleatorizado-de-fase-1b-2 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2969/ifebemtinib-plus-garsorasib-in-previously-treated-metastatic-colorectal-cancer-with-kras-g12c-mutation-a-multicentre-randomised-phase-1b-2-trial 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2890/terapia-con-un-inhibidor-de-puntos-de-control-inmunitario-en-combinacion-o-como-agente-unico-en-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-un-analisis-basado-en-datos-de 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2890/dual-versus-single-agent-immune-checkpoint-inhibitor-therapy-in-microsatellite-instability-high-metastatic-colorectal-cancer-an-analysis-based-on-reconstructed-patient-data 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2883/creacion-de-modelos-tridimensionales-de-cancer-colorrectal-mediante-bioimpresion-y-evaluacion-de-su-eficacia-y-sensibilidad-a-los-farmacos 2026-08-18 monthly 0.5 https://crcwarriors.org/articulo/2883/construction-of-3d-bioprinted-colorectal-cancer-models-and-evaluation-of-their-efficacy-and-drug-sensitivity 2026-08-18 monthly 0.5 https://crcwarriors.org/articulo/2881/las-metastasis-peritoneales-en-el-cancer-de-colon-en-estadio-ii-iii-representan-un-punto-ciego-para-la-vigilancia-del-adn-tumoral-circulante 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2881/peritoneal-metastases-in-stage-ii-iii-colon-cancer-represent-a-blind-spot-for-circulating-tumor-dna-surveillance 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirina-para-la-prevencion-del-cancer-en-individuos-con-sindrome-de-lynch-primeros-resultados-del-ensayo-multicentrico-aleatorizado-doble-ciego-de-no-inferioridad-capp3 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirin-for-cancer-prevention-in-individuals-with-lynch-syndrome-first-results-from-the-capp3-multicentre-randomised-double-blind-non-inferiority-trial 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2828/efectos-antitumorales-de-las-celulas-car-nk92mi-dirigidas-contra-cd133-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2828/anti-tumor-effects-of-cd133-targeted-car-nk92mi-cells-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2826/estrategias-de-administracion-de-virus-oncoliticos-en-los-canceres-gastrointestinales-avances-mecanismos-y-traslacion-clinica 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2826/delivery-strategies-for-oncolytic-viruses-in-gastrointestinal-cancers-progress-mechanisms-and-clinical-translations 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regula-la-metastasis-del-cancer-colorrectal-a-traves-de-la-via-akt-mtor-p70s6k 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/factores-pronosticos-en-el-borde-de-invasion-y-en-el-area-peritumoral-del-cancer-colorrectal-perspectivas-actuales-y-consideraciones-futuras 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2687/dirigirse-a-lig1-para-superar-la-resistencia-al-oxaliplatino-mediante-la-induccion-de-la-panoptosis-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2687/targeting-lig1-to-overcome-oxaliplatin-resistance-by-inducing-panoptosis-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2686/analisis-del-microambiente-inmunosupresor-en-el-cancer-colorrectal-resistente-a-la-quimioterapia-mediante-el-analisis-transcriptomico-de-celulas-individuales 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2686/dissecting-immunosuppressive-microenvironment-in-chemotherapy-resistant-colorectal-cancer-through-single-cell-transcriptomic-analysis 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2675/la-furina-mantiene-las-senales-promotoras-de-tumores-en-el-cancer-colorrectal-con-mutaciones-en-los-genes-kras-y-braf-al-interactuar-con-el-eje-tgf-1-cox-2-en-una-red-de-regulacion-reciproca 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2675/furin-sustains-tumor-promoting-signals-in-kras-and-braf-mutated-colorectal-cancer-by-engaging-the-tgf-1-cox-2-axis-in-a-reciprocal-regulatory-network 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2496/prediccion-de-las-nauseas-inducidas-por-la-quimioterapia-durante-el-tratamiento-con-irinotecan-basandose-en-los-sintomas-previos-inducidos-por-el-oxaliplatino-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2496/prediction-of-chemotherapy-induced-nausea-during-irinotecan-based-treatment-based-on-prior-oxaliplatin-induced-symptoms-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2476/mecanismos-y-desafios-clinicos-de-la-remodelacion-del-microambiente-tumoral-mediada-por-la-inmunoterapia-con-inhibidores-de-puntos-de-control-en-el-carcinoma-nasofaringeo 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2476/mechanisms-and-clinical-challenges-of-icb-mediated-remodeling-of-the-tumor-microenvironment-in-nasopharyngeal-carcinoma 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2475/los-genes-relacionados-con-la-ferroptosis-asociados-con-las-metastasis-hepaticas-del-cancer-colorrectal-modulan-la-peroxidacion-lipidica-en-las-celulas-del-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2475/colorectal-cancer-liver-metastasis-associated-ferroptosis-related-genes-modulate-lipid-peroxidation-in-colorectal-cancer-cells 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2156/caracterizacion-preclinica-y-resultados-de-la-fase-1-de-tqb2102-un-conjugado-anticuerpo-farmaco-biparatopico-her2-de-primera-generacion-en-pacientes-con-tumores-solidos-avanzados 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2156/preclinical-characterization-and-phase-i-results-of-tqb2102-a-first-in-class-her2-biparatopic-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1819/eficacia-y-seguridad-comparativas-de-las-terapias-combinadas-basadas-en-nivolumab-con-ipilimumab-o-binimetinib-en-pacientes-con-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites-y-con 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1819/comparative-efficacy-and-safety-of-nivolumab-based-combination-therapies-with-ipilimumab-or-binimetinib-in-patients-with-microsatellite-stable-and-microsatellite-instability-high-metastatic 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1783/virus-oncoliticos-recubiertos-basados-en-una-estrategia-de-doble-ataque-que-desencadena-la-terapia-car-t-dirigida-a-cd19-en-tumores-gastrointestinales 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1783/coated-oncolytic-viruses-based-double-strike-strategy-triggering-cd19-car-t-therapy-in-gastrointestinal-tumors 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1782/la-fase-logaritmica-como-una-estrategia-terapeutica-evaluacion-de-estrategias-farmacologicas-contra-la-progresion-del-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1782/the-logarithmic-phase-as-a-therapeutic-direction-evaluating-pharmacological-strategies-against-cancer-progression 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1650/eficacia-del-tratamiento-de-primera-linea-y-modelo-pronostico-en-cancer-colorrectal-metastasico-mutante-de-ras-un-estudio-del-mundo-real 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1650/first-line-treatment-efficacy-and-prognostic-model-in-ras-mutant-metastatic-colorectal-cancer-a-real-world-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1188/la-inmunoterapia-en-cancer-colorrectal-avanzado-panorama-actual-mecanismos-desafios-y-direcciones-futuras 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/1188/immunotherapy-in-advanced-colorectal-cancer-current-landscape-mechanisms-challenges-and-future-directions 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2979/valor-pronostico-de-fubp1-en-el-cancer-colorrectal-y-asociacion-con-las-caracteristicas-del-microambiente-inmunitario 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2979/prognostic-value-of-fubp1-in-colorectal-cancer-and-association-with-immune-microenvironment-characteristics 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2978/el-indice-de-masa-corporal-y-la-dislipidemia-influyen-en-la-respuesta-a-la-inmunoterapia-anti-pd-1-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2978/body-mass-index-and-dyslipidemia-influence-responses-to-anti-pd-1-immunotherapy-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2977/se-retira-el-articulo-apoa5-atenua-los-niveles-de-especies-reactivas-de-oxigeno-para-promover-la-resistencia-al-oxaliplatino-en-el-cancer-colorrectal-con-mutaciones-en-pik3ca 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2977/retraction-of-apoa5-alleviates-reactive-oxygen-species-to-promote-oxaliplatin-resistance-in-pik3ca-mutated-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2976/analisis-de-rentabilidad-de-la-terapia-triple-con-encorafenib-binimetinib-y-cetuximab-para-el-tratamiento-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-en-china 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2976/cost-effectiveness-analysis-of-triplet-therapy-of-encorafenib-binimetinib-and-cetuximab-for-treatment-of-metastatic-braf-v600e-mutated-colorectal-cancer-in-china 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2974/biomarcadores-moleculares-epigeneticos-microbianos-y-obtenidos-mediante-biopsia-liquida-integrados-en-el-cancer-colorrectal-implicaciones-para-el-pronostico-y-la-terapia-de-precision 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2974/integrated-molecular-epigenetic-microbial-and-liquid-biopsy-biomarkers-in-colorectal-cancer-implications-for-prognosis-and-precision-therapy 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2972/emb-01-un-anticuerpo-bispecifico-anti-egfr-c-met-en-pacientes-con-cancer-colorrectal-metastasico-muy-avanzado-y-que-han-recibido-multiples-tratamientos-previos-en-un-estudio-de-fase-ib-ii-abierto 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2972/emb-01-an-anti-egfr-c-met-bispecific-antibody-in-patients-with-heavily-pretreated-metastatic-colorectal-cancer-from-a-phase-ib-ii-open-label-multicenter-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2971/la-emodinantrona-un-precursor-natural-de-la-emodina-potencia-la-actividad-antitumoral-de-las-celulas-t-a-traves-de-la-via-de-senalizacion-jak3-stat1-3-y-mejora-la-eficacia-de-los-inhibidores-de-pd-1 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2971/emodinanthrone-a-natural-precursor-of-emodin-enhances-t-cell-anti-tumor-via-jak3-stat1-3-signal-and-improves-anti-pd-1-efficacy-against-colon-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2970/impacto-de-la-inmunoterapia-en-el-tratamiento-del-cancer-de-pulmon-no-microcitico-en-estadio-temprano-el-melanoma-y-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2970/impact-of-immunotherapy-in-the-treatment-of-early-stage-non-small-lung-cancer-melanoma-and-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2968/impacto-pronostico-de-la-dinamica-de-las-mutaciones-circulantes-de-los-genes-ras-y-braf-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2968/prognostic-impact-of-circulating-tumor-ras-and-braf-mutation-dynamics-in-patients-with-metastatic-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2967/la-evolucion-clonal-desde-el-tumor-primario-hasta-el-cancer-de-recto-localmente-recurrente-revela-alteraciones-adquiridas-en-la-recurrencia-que-podrian-ser-susceptibles-de-tratamiento-en-tumores-que 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2967/clonal-evolution-from-primary-to-locally-recurrent-rectal-cancer-reveals-recurrence-acquired-potentially-actionable-alterations-in-treatment-naive-tumors 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2959/un-ensayo-clinico-de-fase-ii-que-evalua-la-reintroduccion-de-la-quimioterapia-con-o-sin-terapia-dirigida-en-pacientes-con-cancer-colorrectal-metastasico-refractario 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2959/a-phase-ii-clinical-trial-of-chemotherapy-rechallenge-with-or-without-targeted-therapy-in-refractory-metastatic-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2958/deficiencia-en-la-reparacion-de-errores-de-emparejamiento-o-inestabilidad-de-microsatelites-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-terapia-neoadyuvante-total 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2958/mismatch-repair-deficiency-or-microsatellite-instability-in-locally-advanced-rectal-cancer-patients-treated-with-total-neoadjuvant-therapy 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2957/estudio-internacional-de-fase-iv-realizado-en-el-ambito-clinico-para-validar-el-cuestionario-de-la-organizacion-europea-para-la-investigacion-y-el-tratamiento-del-cancer-destinado-a-evaluar-la 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2957/international-phase-iv-field-study-to-validate-the-european-organisation-for-research-and-treatment-of-cancer-questionnaire-for-assessing-the-health-related-quality-of-life-of-cancer-survivors-the 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2956/prevalencia-e-impacto-clinico-de-las-alteraciones-en-los-genes-pik3ca-y-pten-detectadas-mediante-analisis-genomicos-reflejos-en-pacientes-con-cancer-colorrectal-de-nuevo-diagnostico-una-serie-basada 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2956/prevalence-and-clinical-impact-of-pik3ca-and-pten-alterations-from-reflex-genomic-testing-of-newly-diagnosed-colorectal-cancer-a-population-based-series 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2950/comparacion-del-analisis-de-la-curva-de-fusion-de-alta-resolucion-basado-en-pcr-y-la-inmunohistoquimica-en-la-deteccion-de-la-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-un-estudio-de 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2950/comparison-of-pcr-based-high-resolution-melting-curve-analysis-and-immunohistochemistry-in-detecting-microsatellite-instability-in-colorectal-cancer-a-retrospective-consistency-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2947/importancia-clinica-de-la-amplificacion-de-erbb2-detectada-mediante-wes-en-el-cancer-colorrectal-resecable 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2947/clinical-significance-of-wes-defined-erbb2-amplification-in-resectable-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2946/mecanismo-de-generacion-de-neoantigenos-y-avances-en-las-inmunoterapias-basadas-en-neoantigenos-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2946/mechanism-of-neoantigen-generation-and-advances-in-neoantigen-based-immunotherapies-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2945/interrupcion-de-la-interaccion-entre-kras-y-ago2-una-estrategia-doble-para-aumentar-la-sensibilidad-a-la-quimioinmunoterapia-en-el-cancer-colorrectal-con-mutacion-en-el-gen-kras 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2945/disrupting-kras-ago2-interaction-a-dual-pronged-strategy-to-sensitize-chemo-immunotherapy-in-kras-mutated-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2943/telisotuzumab-adizutecan-para-el-cancer-colorrectal-metastasico-un-conjugado-anticuerpo-farmaco-dirigido-a-c-met-con-una-carga-de-inhibidor-de-la-topoisomerasa 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2943/telisotuzumab-adizutecan-for-metastatic-colorectal-cancer-a-c-met-targeted-antibody-drug-conjugate-with-a-topoisomerase-inhibitor-payload 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2939/avances-y-retos-en-el-diseno-y-desarrollo-de-farmacos-selectivos-dirigidos-a-la-mutacion-kras-g12d-inhibidores-degradadores-y-estrategias-terapeuticas-emergentes 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2939/progress-and-challenges-in-the-design-and-development-of-selective-kras-g12d-targeted-drug-discovery-inhibitors-degraders-and-emerging-therapeutic-strategies 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2938/inhibicion-de-la-union-raf-mek-con-avutometinib-y-cetuximab-en-el-cancer-colorrectal-metastasico-con-mutacion-s257l-en-el-gen-raf1-y-refractario-al-anti-egfr-en-la-enfermedad-de-gaucher 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2938/raf-mek-clamp-inhibition-with-avutometinib-and-cetuximab-in-raf1-s257l-mutated-anti-egfr-refractory-metastatic-colorectal-cancer-in-gaucher-s-disease 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2937/seguridad-y-eficacia-de-sotorasib-en-combinacion-con-panitumumab-y-folfiri-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-kras-g12c-previamente-tratados-en-el-estudio-codebreak-101-de 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2937/safety-and-efficacy-of-sotorasib-plus-panitumumab-and-folfiri-for-previously-treated-kras-g12c-mutated-metastatic-colorectal-cancer-in-the-codebreak-101-phase-ib-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2933/asociacion-entre-el-numero-de-ganglios-linfaticos-centinela-y-el-pronostico-en-pacientes-con-cancer-de-mama-en-estadio-ct1-2n0m0-y-ganglios-linfaticos-centinela-negativos-un-estudio-retrospectivo-de 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2933/association-between-sentinel-lymph-node-number-and-prognosis-in-ct1-2n0m0-early-breast-cancer-patients-with-negative-sentinel-lymph-nodes-a-single-center-retrospective-cohort-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2932/un-ensayo-de-fase-ii-multicohorte-y-basado-en-biomarcadores-que-evalua-una-terapia-neoadyuvante-total-personalizada-con-agentes-dirigidos-para-el-cancer-de-recto-de-alto-riesgo-el-estudio-trainer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2932/a-multicohort-biomarker-driven-phase-2-trial-of-personalized-total-neoadjuvant-therapy-with-targeted-agents-for-high-risk-rectal-cancer-the-trainer-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2931/capacidad-de-deteccion-de-biomarcadores-de-ctdna-en-diversos-tipos-de-cancer-en-poblaciones-asiaticas-implicaciones-para-la-deteccion-en-un-amplio-espectro-de-canceres 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2931/cross-cancer-detectability-of-ctdna-biomarkers-in-asian-populations-implications-for-pan-cancer-detection 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2930/monoterapia-antitumoral-anti-pd-1-neoadyuvante-seguida-de-una-estrategia-de-observacion-en-pacientes-con-cancer-colorrectal-dmmr-msi-h-un-estudio-multicentrico-en-el-mundo-real 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2930/neoadjuvant-anti-pd-1-monotherapy-followed-by-watch-and-wait-strategy-in-dmmr-msi-h-colorectal-cancer-a-multicenter-real-world-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2929/cancer-colorrectal-metastasico-con-mutacion-kras-g12c-estrategias-terapeuticas-actuales-y-perspectivas-futuras 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2929/kras-g12c-mutated-metastatic-colorectal-cancer-current-therapeutic-strategies-and-future-directions 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2928/los-niveles-basales-de-celulas-t-circulantes-y-tumorales-asi-como-la-expansion-temprana-de-celulas-cd8-pd1-circulantes-predicen-la-respuesta-a-atezolizumab-bevacizumab-en-el-carcinoma-hepatocelular 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2928/baseline-circulating-and-tumor-t-cells-and-early-circulating-cd8-pd1-expansion-predict-response-to-atezolizumab-bevacizumab-in-hcc 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2927/inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localizado-con-dmmr-msi-h-una-revision-sistematica-de-la-respuesta-patologica-y-los-resultados-quirurgicos 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2927/neoadjuvant-immunotherapy-in-localized-dmmr-msi-h-colon-cancer-a-systematic-review-of-pathological-response-and-surgical-outcomes 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2926/nuevas-estrategias-inmunoterapeuticas-para-el-tratamiento-del-cancer-colorrectal-avances-desafios-y-perspectivas-futuras 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2926/novel-immunotherapeutic-strategies-for-colorectal-cancer-treatment-advances-challenges-and-future-directions 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2925/la-dihidropirimidina-deshidrogenasa-modula-la-respuesta-inmune-a-la-inhibicion-de-los-puntos-de-control-en-el-cancer-colorrectal-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2925/dihydropyrimidine-dehydrogenase-modulates-immune-response-to-checkpoint-inhibition-in-mismatch-repair-deficient-microsatellite-instability-high-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2921/la-calibracion-de-la-senalizacion-de-las-celulas-car-promueve-la-division-celular-asimetrica-para-dirigir-el-destino-de-las-celulas-car-t-y-potenciar-su-actividad-antitumoral 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2921/calibration-of-car-signaling-promotes-asymmetric-cell-division-to-direct-car-t-cell-fate-and-antitumor-potency 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2918/comunidades-microbianas-sinteticas-nuevas-terapias-biologicas-vivas-para-la-modulacion-dirigida-del-microbioma-intestinal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2918/synthetic-microbial-communities-emerging-live-biotherapeutics-for-targeted-gut-microbiome-modulation 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2913/inmunoterapia-en-el-cancer-colorrectal-nuevas-perspectivas-y-proximos-pasos 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2913/immunotherapy-in-colorectal-cancer-novel-perspectives-and-next-steps 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2909/modelado-de-los-resultados-clinicos-y-el-impacto-economico-de-la-inmunoterapia-anti-pd-1-pd-l1-en-los-paises-del-golfo-emiratos-arabes-unidos-oman-y-kuwait 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2909/modeling-cancer-outcomes-and-economic-impact-of-the-anti-pd-1-pd-l1-immunotherapy-in-the-gulf-united-arab-emirates-oman-and-kuwait 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2908/eficacia-y-seguridad-de-diferentes-tamanos-de-microesferas-liberadoras-de-farmacos-en-el-tratamiento-de-la-metastasis-hepatica-del-cancer-colorrectal-mediante-tace 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2908/efficacy-and-safety-of-different-sizes-drug-eluting-beads-in-the-treatment-of-colorectal-cancer-liver-metastasis-by-tace 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirina-tras-la-finalizacion-de-la-terapia-adyuvante-estandar-para-el-cancer-colorrectal-ascolt-una-revision-sistematica-y-metaanalisis 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirin-after-completion-of-standard-adjuvant-therapy-for-colorectal-cancer-ascolt-a-systematic-review-and-meta-analysis 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2905/topografia-de-la-heterogeneidad-tumoral-global-wtht-un-nuevo-enfoque-para-la-evaluacion-de-la-heterogeneidad-mutacional-intratumoral-en-adenomas-colorrectales 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2905/whole-tumor-heterogeneity-topography-wtht-a-new-approach-for-assessment-of-intratumor-mutational-heterogeneity-in-colorectal-adenomas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2904/secuenciacion-de-nueva-generacion-en-el-cancer-colorrectal-perfilado-molecular-en-la-practica-clinica-y-correlaciones-clinicas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2904/next-generation-sequencing-in-colorectal-cancer-real-world-molecular-profiling-and-clinical-correlations 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2902/factores-asociados-con-el-momento-de-aparicion-de-metastasis-hepaticas-tras-la-cirugia-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2902/factors-associated-with-the-timing-of-liver-metastasis-after-colorectal-cancer-surgery-a-retrospective-multicenter-study 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2900/el-panorama-genetico-del-cancer-colorrectal-desde-las-alteraciones-moleculares-hasta-las-vias-de-decision-terapeutica 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2900/the-genetic-landscape-of-colorectal-cancer-from-molecular-alterations-to-therapeutic-decision-pathways 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2895/los-n-glicanos-presentes-en-las-celulas-del-microambiente-tumoral-no-maligno-disminuyen-la-funcion-de-las-celulas-car-t-en-tumores-solidos 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2895/n-glycans-in-non-malignant-tumor-microenvironment-cells-dampen-car-t-cell-function-in-solid-tumors 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2893/edicion-precisa-de-las-mutaciones-de-tp53-mediante-la-tecnica-prime-editing-para-lograr-la-supresion-funcional-del-tumor-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2893/precision-prime-editing-of-tp53-mutations-for-functional-tumor-suppression-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2892/prediccion-de-la-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-basada-en-fenotipos-tisulares-inferidos-a-partir-de-imagenes-histopatologicas-completas-mediante-autodestilacion 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2892/prediction-of-microsatellite-instability-in-colorectal-cancer-based-on-tissue-phenotypes-inferred-from-pathological-whole-slide-images-using-self-distillation 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2891/nanocables-de-adn-programables-que-median-la-dispersion-y-la-localizacion-en-el-ensamblaje-catalitico-de-horquillas-para-la-deteccion-y-la-obtencion-de-imagenes-de-alta-resolucion-de-microarn 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2891/programmable-dna-nanowires-mediated-dispersion-to-localization-catalytic-hairpin-assembly-for-high-contrast-mirna-detection-and-imaging 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2887/panorama-emergente-de-la-terapia-con-celulas-car-t-en-el-cancer-de-colon-aspectos-mecanisticos-avances-clinicos-desafios-y-perspectivas-futuras 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2887/emerging-landscape-of-car-t-cell-therapy-in-colon-cancer-mechanistic-insights-clinical-advances-challenges-and-future-directions 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2885/estudio-exhaustivo-del-mecanismo-por-el-cual-xiao-chai-hu-tang-atenua-la-toxicidad-intestinal-inducida-por-irinotecan-y-mejora-la-inmunidad-antitumoral-a-traves-de-la-microbiota-intestinal-y-la 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2885/in-depth-study-on-the-mechanism-of-xiao-chai-hu-tang-in-ameliorating-irinotecan-induced-intestinal-toxicity-and-enhancing-antitumor-immunity-via-intestinal-microbiota-and-fecal-metabolomics 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2884/el-extracto-de-paliurus-ramosissimus-alivia-parcialmente-la-colitis-asociada-al-cancer-colorrectal-inducido-por-aom-dss-en-ratones-hallazgos-obtenidos-a-partir-de-analisis-transcriptomicos-y-del 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2884/paliurus-ramosissimus-extract-partially-ameliorates-aom-dss-induced-colitis-associated-colorectal-cancer-in-mice-insights-from-transcriptomic-and-gut-microbiota-analyses 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2882/el-metabolismo-mitocondrial-y-las-firmas-genicas-relacionadas-con-la-succinilacion-como-predictores-del-pronostico-y-la-resistencia-a-los-farmacos-en-el-adenocarcinoma-de-colon 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2882/mitochondrial-metabolism-and-succinylation-related-gene-signatures-for-predicting-prognosis-and-drug-resistance-in-colon-adenocarcinoma 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2880/caracterizacion-molecular-de-las-metastasis-ovaricas-derivadas-del-cancer-colorrectal-mediante-el-analisis-del-adn-tumoral-circulante 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2880/molecular-characterization-of-ovarian-metastases-from-colorectal-cancer-using-circulating-tumor-dna-analysis 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2879/desarrollo-de-inmunoterapia-con-criterios-farmacodinamicos-pd-y-adaptada-a-las-caracteristicas-del-tumor-en-el-cancer-colorrectal-mss-pmmr 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2879/barrier-matched-pharmacodynamic-pd-gated-immunotherapy-development-in-mss-pmmr-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2878/supresion-dirigida-de-kras-en-el-cancer-colorrectal-mediante-arn-de-interferencia-de-doble-cadena-siarn-autoensamblados-in-vivo-y-encapsulados-en-pequenas-vesiculas-extracelulares-endogenas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2878/targeted-kras-suppression-in-colorectal-cancer-via-in-vivo-self-assembled-sirnas-encapsulated-in-endogenous-small-extracellular-vesicles 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2873/proceso-de-radiomica-de-tc-coclinica-para-identificar-posibles-biomarcadores-de-imagen-para-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2873/co-clinical-ct-radiomics-pipeline-to-establish-candidate-imaging-biomarkers-for-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2872/el-lncrna-miat-modificado-con-m-6-a-promueve-la-resistencia-a-la-anoikis-y-la-metastasis-peritoneal-del-cancer-colorrectal-a-traves-del-eje-de-senalizacion-mir-181a-5p-mcl1 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2872/m-6-a-modified-lncrna-miat-promotes-anoikis-resistance-and-peritoneal-metastasis-of-colorectal-cancer-through-mir-181a-5p-mcl1-signaling-axis 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2871/analisis-de-coste-efectividad-de-nivolumab-mas-ipilimumab-frente-a-nivolumab-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados-y-con-deficiencia-en-la-reparacion-del 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2871/cost-effectiveness-analysis-of-nivolumab-plus-ipilimumab-versus-nivolumab-monotherapy-in-previously-treated-metastatic-colorectal-cancer-patients-with-dna-mismatch-repair-deficient-microsatellite 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2870/desde-la-inhibicion-de-kras-hasta-la-adaptacion-tumoral-mecanismos-de-resistencia-y-estrategias-terapeuticas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2870/from-kras-inhibition-to-tumor-adaptation-mechanistic-layers-of-resistance-and-therapeutic-strategies 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2863/panorama-de-los-ensayos-clinicos-y-perspectivas-traslacionales-de-la-inmunoterapia-basada-en-celulas-asesinas-naturales-un-analisis-basado-en-la-base-de-datos-informa 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2863/clinical-trial-landscape-and-translational-prospects-of-natural-killer-cell-based-immunotherapy-an-analysis-based-on-the-informa-database 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2862/informe-breve-beneficio-terapeutico-de-isa-2011b-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2862/brief-report-therapeutic-benefit-of-isa-2011b-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2861/modulacion-de-la-microbiota-intestinal-en-los-canceres-gastrointestinales-desde-las-caracteristicas-de-la-disbiosis-hasta-las-intervenciones-terapeuticas 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2861/gut-microbiota-modulation-of-gastrointestinal-cancers-from-dysbiosis-signatures-to-therapeutic-interventions 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2859/relacion-entre-los-sitios-de-mutacion-del-gen-kras-y-las-caracteristicas-clinicas-en-el-cancer-colorrectal 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2859/relationship-between-kras-gene-mutation-sites-and-clinical-characteristics-in-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2858/panorama-genomico-e-implicaciones-terapeuticas-del-cancer-colorrectal-con-fusion-de-alk 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2858/genomic-landscape-and-therapeutic-implications-of-anaplastic-lymphoma-kinase-fusion-positive-colorectal-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2857/predictores-genomicos-transcriptomicos-y-moleculares-de-la-respuesta-a-la-terapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-una-revision-narrativa 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2857/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-narrative-review 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2852/un-modelo-de-radiomica-predice-la-eficacia-de-un-inhibidor-de-cdk4-6-en-primera-linea-combinado-con-terapia-endocrina-en-el-cancer-de-mama-avanzado-hr-her2 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2852/radiomics-model-predicts-efficacy-of-first-line-cdk4-6-inhibitor-combined-with-endocrine-therapy-in-hr-her2-advanced-breast-cancer 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2847/fototerapia-inmunoterapia-del-carcinoma-de-colon-mediante-un-complejo-de-nanoparticulas-de-carbono-y-fe-ii-con-un-inmunoadyuvante 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2847/photothermal-immunotherapy-of-colon-carcinoma-by-carbon-nanoparticle-fe-ii-complex-with-immunoadjuvant 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2846/prediccion-multimodelo-del-pronostico-especifico-por-estadio-del-cancer-colorrectal-mediante-el-aprendizaje-profundo-en-conjunto-basado-en-la-atencion-aplicado-a-datos-de-perfiles-genomicos 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2846/a-multi-model-prediction-of-a-stage-specific-prognosis-for-colorectal-cancer-using-attention-driven-deep-ensemble-learning-on-genomic-profiling-data 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2839/adicion-de-altas-dosis-de-vitamina-d3-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-metastasico-el-ensayo-clinico-aleatorizado-solaris-alliance-a021703 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2839/addition-of-high-dose-vitamin-d3-to-standard-treatment-in-patients-with-metastatic-colorectal-cancer-the-solaris-randomized-clinical-trial-alliance-a021703 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2838/el-analisis-especifico-de-variantes-del-fenomeno-de-exclusion-mutua-entre-los-oncogenes-braf-egfr-y-kras-revela-una-superposicion-con-pares-de-mutantes-funcionalmente-antagonicos 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2838/variant-specific-landscape-of-mutual-exclusivity-among-braf-egfr-and-kras-oncogenes-reveals-overlap-with-functionally-antagonistic-mutant-pairs 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2834/asociacion-de-los-macrofagos-intratumorales-cd68-cd163-de-tipo-m2-con-la-supervivencia-en-el-cancer-colorrectal-metastasico-tratado-con-quimioterapia-mas-bevacizumab 2026-08-26 monthly 0.5 https://crcwarriors.org/articulo/2834/association-of-intratumoral-cd68-cd163-m2-like-macrophages-with-survival-in-metastatic-colorectal-cancer-treated-with-chemotherapy-plus-bevacizumab 2026-08-26 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-08-23 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-08-24 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-08-25 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-08-23 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-08-01 monthly 0.4